Galderma's Acne Drug Switch Gets Unanimous NDAC Support
This article was originally published in The Rose Sheet
Executive Summary
If approved by FDA, the product, to be marketed as Differin Gel, would be the first OTC drug available in the US that contains an ingredient in the retinoid class – adapalene 0.1 gel. Discussion at the April 15 meeting of FDA's Nonprescription Drugs Advisory Committee focused largely on the issue of self-selection among pregnant women.
You may also be interested in...
Galderma Pioneers NDA Path Into OTC Acne Treatment Market
FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical acne treatment for consumers 12 years old and up.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.